Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Biopharma develops therapeutic antibodies and combination therapies for autoimmune diseases and immuno-oncology, addressing unmet medical needs.
Kanova Biopharma, based in Suzhou, Jiangsu province, China, develops first-in-class therapeutic antibodies and innovative combination therapies for autoimmune diseases and immuno-oncology. The company has raised a total of $30.57 million in funding, including a recent $14 million Series B-II round led by Suzhou Gaote Jiaxin Yinhuixin Fund, with Northern Light Venture Capital and CD Capital among investors. Its pipeline includes XKH-001, currently in Phase 3 for moderate atopic dermatitis, alongside other candidates like XKH004 (IL-17A/F). Employee count is not disclosed, but the company leverages proprietary technology platforms for its R&D efforts. Founded in November 2015 by world-renowned immunologist Chen Dong, the company appointed Yaning Wang as CEO in December 2020. Its business model centers on venture capital-funded biotech focused on R&D of antibody drugs, generates no revenue yet, sustains through equity financing rounds.
Kanova has raised $16.6M across 1 funding round.
Kanova has raised $16.6M in total across 1 funding round.
Kanova has raised $16.6M in total across 1 funding round.
Kanova's investors include bioVENTURE, Kington Capital, Northern Light Venture Capital.
Kanova has raised $16.6M across 1 funding round. Most recently, it raised $16.6M Series A in November 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 26, 2018 | $16.6M Series A | — | BioVenture, Kington Capital, Northern Light Venture Capital | Announced |